Dexcom (DXCM) reported Q4 2025 earnings exceeding forecasts with an EPS of $0.68 and revenue of $1.26 billion, yet its stock dipped 4.45% in after-hours trading. The company highlighted strong international growth, the launch of the Dexcom G7 15-day system, and anticipates Medicare coverage expansion for new patient segments. Dexcom also provided a robust 2026 revenue guidance between $5.16 billion and $5.25 billion, expecting continued growth driven by product innovation and market expansion.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Earnings call transcript: Dexcom Q4 2025 beats forecasts, stock dips
Dexcom (DXCM) reported Q4 2025 earnings exceeding forecasts with an EPS of $0.68 and revenue of $1.26 billion, yet its stock dipped 4.45% in after-hours trading. The company highlighted strong international growth, the launch of the Dexcom G7 15-day system, and anticipates Medicare coverage expansion for new patient segments. Dexcom also provided a robust 2026 revenue guidance between $5.16 billion and $5.25 billion, expecting continued growth driven by product innovation and market expansion.